Business
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025SYDNEY, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces the successful conduct of its scheduled Type C meeting (written response) on Alzheimer’s disease (AD) with the US Food & Drug Administration (FDA). Actinogen and the FDA reached a common understanding of the pathway to marketing approval in AD - m
About this update from Actinogen Medical Limited
[{"type":"image","alt":"Actinogen Medical","displaySize":"","headline":null,"caption":"Actinogen Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TQImuMTxtef96v4yTMESFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3b4990d3680eb8b749faad86ae930ad4","width":300,"height":300}},"lazy":false},{"type":"text","content":"Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025","length":163,"tagName":"p"},{"type":"text","content":"SYDNEY, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces the successful conduct of its scheduled Type C meeting (written response) on Alzheimer’s disease (AD) with the US Food & Drug Administration (FDA).","length":241,"tagName":"p"},{"type":"text","content":"Actinogen and the FDA reached a common understanding of the pathway to marketing approval in AD - meaning agreement on regulatory starting materials in drug substance synthesis, the design of one additional pivotal clinical trial and the limited number of ancillary clinical pharmacology trials and nonclinical studies required. Key understandings include the:","length":360,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"‘Regulatory starting materials‘ for the commercial manufacturing of Xanamem® (emestedastat) drug substance","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"General design of the interim analysis for XanaMIA","length":50,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Design of one additional, well-controlled, pivotal (phase 3) trial to support a positive XanaMIA pivotal trial","length":110,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Single emestedastat dose design (10 mg vs placebo) for the planned pivotal Phase 3 trial","length":88,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Number of people to be treated with Xanamem to be described in the New Drug Application (NDA) – that is, the makeup of the planned safety database consistent with FDA guidelines","length":177,"tagName":"p","attri...